Another study found that MAGE-C2/CT10 was expressed in 3.3% of primary prostate cancer tissues, significantly higher expression of MAGE-C2/CT10 protein in metastatic prostate cancer and castrated prostate cancer (16.3% and 17%, respectively), and lower survival in MAGE-C2/CT10 positive patients [12]. This evidence concerns the gene MAGEC2 and prostate carcinoma.